Convalescent patient-derived monoclonal antibodies targeting different epitopes of E protein confer protection against Zika virus in a neonatal mouse model

References

• Lazear HM, Diamond MS, Pierson TC. Zika virus: new clinical syndromes and its emergence in the Western Hemisphere. J Virol. 2016;90:4864–4875. doi: 10.1128/JVI.00252-16
   PubMed Web of Science ®Google Scholar
• Gatherer D, Kohl A. Zika virus: a previously slow pandemic spreads rapidly through the Americas. J Gen Virol. 2016;97:269–273. doi: 10.1099/jgv.0.000381
   PubMed Web of Science ®Google Scholar
• Joguet G, Mansuy J-M, Matusali G, et al. Effect of acute Zika virus infection on sperm and virus clearance in body fluids: a prospective observational study. Lancet Infect Dis. 2017;17:1200–1208. doi: 10.1016/S1473-3099(17)30444-9
   PubMed Web of Science ®Google Scholar
• Pierson TC, Diamond MS. The emergence of Zika virus and its new clinical syndromes. Nature. 2018;560:573–581. doi: 10.1038/s41586-018-0446-y
   PubMed Web of Science ®Google Scholar
• Dick G, Kitchen S, Haddow A. Zika virus (I). Isolations and serological specificity. Trans R Soc Trop Med Hyg. 1952;46:509–520. doi: 10.1016/0035-9203(52)90042-4
   PubMed Web of Science ®Google Scholar
• Hayes EB. Zika virus outside Africa. Emerg Infect Dis. 2009;15:1347–1350. doi: 10.3201/eid1509.090442
   PubMed Web of Science ®Google Scholar
• Liu Y, Liu J, Du S, et al. Evolutionary enhancement of Zika virus infectivity in Aedes aegypti mosquitoes. Nature. 2017;545:482–486. doi: 10.1038/nature22365
   PubMed Web of Science ®Google Scholar
• Lessler J, Chaisson LH, Kucirka LM, et al. Assessing the global threat from Zika virus. Science. 2016;353:aaf8160. doi: 10.1126/science.aaf8160
   PubMed Web of Science ®Google Scholar
• McArthur M. Zika virus: recent advances towards the development of vaccines and therapeutics. Viruses. 2017;9:143. doi: 10.3390/v9060143
   PubMed Web of Science ®Google Scholar
• Cao-Lormeau V-M, Blake A, Mons S, et al. Guillain-Barré syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control study. The Lancet. 2016;387:1531–1539. doi: 10.1016/S0140-6736(16)00562-6
   PubMed Web of Science ®Google Scholar
• Schuler-Faccini L, Ribeiro EM, Feitosa IM, et al. Possible association between Zika virus infection and microcephaly - Brazil, 2015. MMWR Morb Mort Wkly Rep. 2016;65:59–62. doi: 10.15585/mmwr.mm6503e2
   PubMed Web of Science ®Google Scholar
• Mlakar J, Korva M, Tul N, et al. Zika virus associated with microcephaly. N Engl J Med. 2016;374:951–958. doi: 10.1056/NEJMoa1600651
   PubMed Web of Science ®Google Scholar
• Sirohi D, Chen Z, Sun L, et al. The 3.8Å resolution cryo-EM structure of Zika virus. Science. 2016;352:467–470. doi: 10.1126/science.aaf5316
   PubMed Web of Science ®Google Scholar
• Kostyuchenko VA, Lim EX, Zhang S, et al. Structure of the thermally stable Zika virus. Nature. 2016;533:425–428. doi: 10.1038/nature17994
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zhang W, Ogata S, et al. Conformational changes of the flavivirus E glycoprotein. Structure. 2004;12:1607–1618. doi: 10.1016/j.str.2004.06.019
   PubMed Web of Science ®Google Scholar
• Smit J, Moesker B, Rodenhuis-Zybert I, et al. Flavivirus cell entry and membrane fusion. Viruses. 2011;3:160–171. doi: 10.3390/v3020160
   PubMed Web of Science ®Google Scholar
• Cockburn JJ, Navarro Sanchez ME, Goncalvez AP, et al. Structural insights into the neutralization mechanism of a higher primate antibody against dengue virus. EMBO J. 2012;31:767–779. doi: 10.1038/emboj.2011.439
   PubMed Web of Science ®Google Scholar
• Dai L, Song J, Lu X, et al. Structures of the Zika virus envelope protein and its complex with a flavivirus broadly protective antibody. Cell Host Microbe. 2016;19:696–704. doi: 10.1016/j.chom.2016.04.013
   PubMed Web of Science ®Google Scholar
• Rey F, Heinz F, Mandl C, et al. The envelope glycoprotein from tick-borne encephalitis virus at 2Å resolution. Nature. 1995;375:291–298. doi: 10.1038/375291a0
   PubMed Web of Science ®Google Scholar
• Stiasny K, Kössl C, Lepault J, et al. Characterization of a structural intermediate of flavivirus membrane fusion. PLoS Pathog. 2007;3:e20. doi: 10.1371/journal.ppat.0030020
   PubMed Web of Science ®Google Scholar
• Robbiani DF, Bozzacco L, Keeffe JR, et al. Recurrent potent human neutralizing antibodies to Zika virus in Brazil and Mexico. Cell. 2017;169:597–609.e11. doi: 10.1016/j.cell.2017.04.024
   PubMed Web of Science ®Google Scholar
• Sapparapu G, Fernandez E, Kose N, et al. Neutralizing human antibodies prevent Zika virus replication and fetal disease in mice. Nature. 2016;540:443–447. doi: 10.1038/nature20564
   PubMed Web of Science ®Google Scholar
• Stettler K, Beltramello M, Espinosa DA, et al. Specificity, cross-reactivity, and function of antibodies elicited by Zika virus infection. Science. 2016;353:823–826. doi: 10.1126/science.aaf8505
   PubMed Web of Science ®Google Scholar
• Wang Q, Yang H, Liu X, et al. Molecular determinants of human neutralizing antibodies isolated from a patient infected with Zika virus. Sci Transl Med. 2016;8:369ra179–369ra179. doi: 10.1126/scitranslmed.aai8336
   PubMed Web of Science ®Google Scholar
• Yu L, Wang R, Gao F, et al. Delineating antibody recognition against Zika virus during natural infection. JCI Insight. 2017;2:e93042. doi: 10.1172/jci.insight.93042
   PubMed Web of Science ®Google Scholar
• Zhang F-C, Li X-F, Deng Y-Q, et al. Excretion of infectious Zika virus in urine. Lancet Infect Dis. 2016;16:641–642. doi: 10.1016/S1473-3099(16)30070-6
   PubMed Web of Science ®Google Scholar
• Wu X, Zhang Z, Schramm CA, et al. Maturation and diversity of the VRC01-antibody lineage over 15 years of chronic HIV-1 infection. Cell. 2015;161:470–485. doi: 10.1016/j.cell.2015.03.004
   PubMed Web of Science ®Google Scholar
• Liao H-X, Levesque MC, Nagel A, et al. High-throughput isolation of immunoglobulin genes from single human B cells and expression as monoclonal antibodies. J Virol Methods. 2009;158:171–179. doi: 10.1016/j.jviromet.2009.02.014
   PubMed Web of Science ®Google Scholar
• Brochet X, Lefranc M-PP, Giudicelli V. IMGT/V-QUEST: The highly customized and integrated system for IG and TR standardized V-J and V-D-J sequence analysis. Nucleic Acids Res. 2008;36:W503–W508. doi: 10.1093/nar/gkn316
   PubMed Web of Science ®Google Scholar
• Meng W, Pan W, Zhang AJ, et al. Rapid generation of human-like neutralizing monoclonal antibodies in urgent preparedness for influenza pandemics and virulent infectious diseases. PLoS ONE. 2013;8:e66276. doi: 10.1371/journal.pone.0066276
   PubMed Web of Science ®Google Scholar
• Kraus AA, Messer W, Haymore LB, et al. Comparison of plaque- and flow cytometry-based methods for measuring dengue virus neutralization. J Clin Microbiol. 2007;45:3777–3780. doi: 10.1128/JCM.00827-07
   PubMed Web of Science ®Google Scholar
• Davidson E, Doranz BJ. A high-throughput shotgun mutagenesis approach to mapping B-cell antibody epitopes. Immunology. 2014;143:13–20. doi: 10.1111/imm.12323
   PubMed Web of Science ®Google Scholar
• Dejnirattisai W, Wongwiwat W, Supasa S, et al. A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus. Nature Immunol. 2015;16:170–177. doi: 10.1038/ni.3058
   PubMed Web of Science ®Google Scholar
• Wrammert J, Smith K, Miller J, et al. Rapid cloning of high-affinity human monoclonal antibodies against influenza virus. Nature. 2008;453:667–671. doi: 10.1038/nature06890
   PubMed Web of Science ®Google Scholar
• Zhou T, Lynch RM, Chen L, et al. Structural repertoire of HIV-1-neutralizing antibodies targeting the CD4 supersite in 14 donors. Cell. 2015;161:1280–1292. doi: 10.1016/j.cell.2015.05.007
   PubMed Web of Science ®Google Scholar
• Corti D, Zhao J, Pedotti M, et al. Prophylactic and postexposure efficacy of a potent human monoclonal antibody against MERS coronavirus. Proc Natl Acad Sci USA. 2015;112:10473–10478. doi: 10.1073/pnas.1510199112
   PubMed Web of Science ®Google Scholar
• Ying T, Du L, Ju T, et al. Exceptionally potent neutralization of Middle East respiratory syndrome coronavirus by human monoclonal antibodies. J Virol. 2014;88:7796–7805. doi: 10.1128/JVI.00912-14
   PubMed Web of Science ®Google Scholar
• Zhang Q, Gui M, Niu X, et al. Potent neutralizing monoclonal antibodies against Ebola virus infection. Sci Rep. 2016;6:25856. doi: 10.1038/srep25856
   PubMed Web of Science ®Google Scholar
• Wang J, Bardelli M, Espinosa DA, et al. A human bi-specific antibody against Zika virus with high therapeutic potential. Cell. 2017;171:229–241.e15. doi: 10.1016/j.cell.2017.09.002
   PubMed Web of Science ®Google Scholar
• Magnani DM, Rogers TF, Beutler N, et al. Neutralizing human monoclonal antibodies prevent Zika virus infection in macaques. Sci Transl Med. 2017;9:eaan8184. doi: 10.1126/scitranslmed.aan8184
   PubMed Web of Science ®Google Scholar
• Wang Q, Yan J, Gao GF. Monoclonal antibodies against Zika virus: therapeutics and their implications for vaccine design. J Virol. 2017;91:e01049–17.
   PubMed Web of Science ®Google Scholar
• Zhao H, Fernandez E, Dowd KA, et al. Structural basis of Zika virus-specific antibody protection. Cell. 2016;166:1016–1027. doi: 10.1016/j.cell.2016.07.020
   PubMed Web of Science ®Google Scholar
• Deng Y-QQ, Dai J-XX, Ji G-HH, et al. A broadly flavivirus cross-neutralizing monoclonal antibody that recognizes a novel epitope within the fusion loop of E protein. PloS ONE. 2011;6:e16059. doi: 10.1371/journal.pone.0016059
   PubMed Web of Science ®Google Scholar
• Dejnirattisai W, Supasa P, Wongwiwat W, et al. Dengue virus sero-cross-reactivity drives antibody-dependent enhancement of infection with zika virus. Nature Immunol. 2016;17:1102–1108. doi: 10.1038/ni.3515
   PubMed Web of Science ®Google Scholar
• Abbink P, Larocca RA, Dejnirattisai W, et al. Therapeutic and protective efficacy of a dengue antibody against Zika infection in rhesus monkeys. Nature Med. 2018;24:721–723. doi: 10.1038/s41591-018-0056-0
   PubMed Web of Science ®Google Scholar
• Fernandez E, Dejnirattisai W, Cao B, et al. Human antibodies to the dengue virus E-dimer epitope have therapeutic activity against Zika virus infection. Nature Immunol. 2017;18:1261–1269. doi: 10.1038/ni.3849
   PubMed Web of Science ®Google Scholar
• Hasan S, Miller A, Sapparapu G, et al. A human antibody against Zika virus crosslinks the E protein to prevent infection. Nature Comm. 2017;8:14722. doi: 10.1038/ncomms14722
   PubMed Web of Science ®Google Scholar
• Long F, Doyle M, Fernandez E, et al. Structural basis of a potent human monoclonal antibody against Zika virus targeting a quaternary epitope. Proc Natl Acad Sci USA. 2019;116:1591–1596. doi: 10.1073/pnas.1815432116
   PubMed Web of Science ®Google Scholar
• Lazear HM, Govero J, Smith A, et al. A mouse model of Zika virus pathogenesis. Cell Host Microbe. 2016;19:720–730. doi: 10.1016/j.chom.2016.03.010
   PubMed Web of Science ®Google Scholar
• Manangeeswaran M, Ireland DD, Verthelyi D. Zika (PRVABC59) infection is associated with T cell infiltration and neurodegeneration in CNS of immunocompetent neonatal C57Bl/6 mice. PLoS Pathog. 2016;12:e1006004. doi: 10.1371/journal.ppat.1006004
   PubMed Web of Science ®Google Scholar
• Aliota MT, Caine EA, Walker EC, et al. Characterization of lethal Zika virus infection in AG129 mice. PLOS Negl Trop Dis. 2016;10:e0004682. doi: 10.1371/journal.pntd.0004682
   PubMed Web of Science ®Google Scholar